56356-90-2

Basic information

• Product Name: C₇H₅Cl₂NS₂
• Synonyms: C₇H₅Cl₂NS₂
• CAS NO: 56356-90-2
• Molecular Weight: 238.161
• Mol File: 56356-90-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: C₇H₅Cl₂NS₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₇H₅Cl₂NS₂(56356-90-2)
• EPA Substance Registry System: C₇H₅Cl₂NS₂(56356-90-2)

Safety Data

• Hazardous Substances Data: 56356-90-2(Hazardous Substances Data)

Upstream product

• 75-15-0 carbon disulfide 
• 554-00-7 2,4-Dichloroaniline 

Downstream Products

• 6590-96-1 2, 4-dichlorophenyl isothiocyanate 
• 1412891-41-8 4-(3-(3-(2,4-dichlorophenyl)thioureido)phenoxy)-N-methylpicolinamide 
• 1417341-21-9 1-(2,4-dichlorophenyl)-3-(4-(2-(pyrrolidine-1-carbonyl)pyridin-4-yloxy)phenyl)thiourea 
• 1417341-31-1 1-(2,4-dichlorophenyl)-3-(4-(2-(pyrrolidine-1-carbonyl)pyridin-4-ylthio)phenyl)thiourea 
• 1395063-43-0 N-benzyl-4-(4-(3-(2,4-dichlorophenyl)thioureido)phenylthio)picolinamide 

Relevant articles and documents

Design, synthesis and biological evaluation of thiourea and nicotinamide-containing sorafenib analogs as antitumor agents

A series of thiourea and nicotinamide-containing sorafenib analogs (7a-n) were designed and synthesized and their antiproliferative activities were tested against HCT116, MDA-MB-231, PC-3 and HepG2 cell lines. Most of the compounds showed potent activities against the four cell lines, compound 7h showed better activities than sorafenib against all four cell lines, and compounds 7a and 7e showed better activities against HCT116 and MDA-MB-231 cell lines. The anti-angiogenic activities of 7e and 7h were also better than that of sorafenib in both in vitro HUVEC tube formation assay and ex vivo rat thoracic aorta ring assay.

Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors

VEGFR-2, TIE-2, and EphB4 are essential for both angiogenesis and tumorigenesis. Herein, we designed and prepared three classes of multi-target inhibitors based on the extensive sequence homology along the kinase domain of angiogenic RTKs. Biological evaluation indicated that these multi-target inhibitors exhibited considerable potential as novel anti-angiogeneic and anticancer agents. Among them, a diaryl thiourea bearing 1H-indazole-3-amine (16a) displayed the most potent RTK inhibition and excellent selectivity. It also showed inhibition on viability of human umbilical vein endothelial cells and anti-proliferation against a broad spectrum of cancer cells. Therefore, 1H-indazole-3-amine could serve as a promising hinge binding group for multi-target inhibitors of VEGFR-2, Tie-2, and EphB4.

Design, synthesis and biological activities of sorafenib derivatives as antitumor agents

A series of novel sorafenib derivatives, 9a-w, was designed and synthesized in high yields using various substituted anilines, and their antiproliferative activities against HCT116, PC-3 and MDA-MB-231 cell lines were also evaluated and described. All compounds exhibited potent antiproliferative activity against HCT116 and PC-3 cells with IC50 = 2.8-52.0 and 2.2-45.6 μM; compounds 9p and 9q demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines, the cytotoxicity of compound 9r is more potent than that of sorafenib. Compounds (9g, 9p, 9q and 9r) were chosen for further evaluation of the anti-angiogenesis activity, and showed the inhibition of sprout formation from aortic ring ex vivo. The structures of all the newly synthesized compounds were determined by 1H NMR, 13C NMR and HRMS.